Astera Labs (NASDAQ:ALAB) Releases Q1 2026 Earnings Guidance

Astera Labs (NASDAQ:ALAB) updated its first quarter 2026 earnings guidance on Tuesday. The company provided earnings per share (EPS) guidance of 0.530-0.540 for the period, compared to the consensus estimate of 0.430. The company issued revenue guidance of $286.0 million-$297.0 million, compared to the consensus revenue estimate of $260.1 million.

Astera Labs Stock Down 19.6%

NASDAQ:ALAB traded down $35.92 during trading hours on Wednesday, hitting $146.94. 9,540,235 shares of the stock were exchanged, compared to its average volume of 5,319,016. The company has a market capitalization of $24.82 billion, a P/E ratio of 132.65, a price-to-earnings-growth ratio of 2.56 and a beta of 1.50. The company’s 50 day moving average is $165.43 and its two-hundred day moving average is $174.63. Astera Labs has a twelve month low of $47.13 and a twelve month high of $262.90.

Astera Labs (NASDAQ:ALAB) last announced its quarterly earnings results on Tuesday, February 10th. The company reported $0.58 earnings per share for the quarter, topping analysts’ consensus estimates of $0.51 by $0.07. The company had revenue of $270.58 million for the quarter, compared to analysts’ expectations of $249.46 million. Astera Labs had a net margin of 27.50% and a return on equity of 13.48%. The business’s quarterly revenue was up 91.8% compared to the same quarter last year. During the same period last year, the firm posted $0.37 earnings per share. Astera Labs has set its Q1 2026 guidance at 0.530-0.540 EPS. On average, equities research analysts expect that Astera Labs will post 0.34 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on ALAB shares. Needham & Company LLC raised their price target on shares of Astera Labs from $205.00 to $220.00 and gave the stock a “buy” rating in a research note on Wednesday, November 5th. Morgan Stanley reaffirmed an “overweight” rating and issued a $210.00 target price on shares of Astera Labs in a research report on Wednesday, December 3rd. Royal Bank Of Canada initiated coverage on shares of Astera Labs in a research report on Wednesday, January 14th. They set an “outperform” rating and a $225.00 price target on the stock. Weiss Ratings restated a “hold (c-)” rating on shares of Astera Labs in a report on Wednesday, January 21st. Finally, Roth Mkm lifted their target price on Astera Labs from $200.00 to $225.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Fourteen research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $192.89.

Insider Buying and Selling at Astera Labs

In related news, CFO Michael Truett Tate sold 11,430 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $144.69, for a total value of $1,653,806.70. Following the sale, the chief financial officer directly owned 192,297 shares of the company’s stock, valued at $27,823,452.93. This trade represents a 5.61% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Philip Mazzara sold 4,620 shares of Astera Labs stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $144.69, for a total value of $668,467.80. Following the completion of the transaction, the general counsel owned 147,040 shares in the company, valued at approximately $21,275,217.60. This represents a 3.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 576,936 shares of company stock worth $87,409,540 over the last three months. 12.50% of the stock is owned by corporate insiders.

Key Stories Impacting Astera Labs

Here are the key news stories impacting Astera Labs this week:

• Positive Sentiment: Q4 results beat consensus: Astera Labs reported $0.58 EPS vs. $0.51 expected and record quarterly revenue of $270.6M (up 17% QoQ, 91.8% YoY). This confirms strong demand for its AI infrastructure connectivity products. Astera Labs Reports Fourth Quarter and Full Year 2025 Financial Results
• Positive Sentiment: Strong Q1 2026 guidance: management gave EPS guidance of $0.530–$0.540 and revenue guidance (~$286M–$297M) well above street consensus, and CEO emphasized long-term AI opportunity — a bullish indicator for future growth. Astera Labs shares sink 10% as revenue comes up short of some expectations
• Neutral Sentiment: Analyst target adjusted: Citigroup trimmed its price target from $275 to $250 but kept a Buy rating, leaving a large implied upside — a mixed signal for investors weighing valuation vs. momentum. Citigroup price target cut
• Neutral Sentiment: CFO transition announced: Desmond Lynch named CFO while prior CFO moves to strategic advisor — operational change that appears orderly but worth monitoring for execution risk. Astera Labs press release (CFO appointment)
• Neutral Sentiment: Product/R&D expansion: opened Israel R&D centers to broaden engineering capacity — supports long-term roadmap but not an immediate catalyst. Astera Labs opens Israel R&D centers
• Negative Sentiment: Stock sold off despite beats: several outlets reported sharp declines and heavy intraday/after-hours selling after the print — investors focused on any metric that “missed some analysts’ expectations” and took profits after a steep run to an all-time high. Here’s why Astera Labs stock price crashed despite strong earnings report
• Negative Sentiment: Some headlines framed revenue as short of certain expectations and noted the stock fell ~10% in early coverage — negative press can amplify selling even when fundamentals are solid. Astera Labs stock drops despite solid Q4 results, guidance

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Amundi grew its stake in shares of Astera Labs by 1,298.6% during the 3rd quarter. Amundi now owns 1,421,263 shares of the company’s stock valued at $278,283,000 after acquiring an additional 1,319,643 shares during the period. Voloridge Investment Management LLC bought a new position in Astera Labs in the 3rd quarter worth $131,539,000. Holocene Advisors LP purchased a new stake in Astera Labs in the 2nd quarter worth $55,827,000. State Street Corp lifted its position in shares of Astera Labs by 39.3% in the second quarter. State Street Corp now owns 2,143,459 shares of the company’s stock valued at $193,812,000 after acquiring an additional 604,363 shares in the last quarter. Finally, Qube Research & Technologies Ltd bought a new position in shares of Astera Labs in the third quarter worth about $111,291,000. 60.47% of the stock is owned by hedge funds and other institutional investors.

Astera Labs Company Profile

Astera Labs is a fabless semiconductor company that develops connectivity solutions for data center and cloud infrastructure. The firm focuses on addressing signal integrity and link management challenges that arise as server architectures incorporate higher-bandwidth processors and accelerators. Its technology is aimed at improving reliability and performance for high-speed interconnects used in servers, storage systems and compute accelerators.

The company’s product portfolio centers on silicon devices and accompanying firmware and software that enhance and manage high-speed links.